Objectives: As information on Ureaplasma spp. and Mycoplasma hominis resistance is currently limited, the aim of this study was to investigate the susceptibility of Ureaplasma spp. and M. hominis to tetracyclines and fluoroquinolones in France.
Introduction
Ureaplasma urealyticum, Ureaplasma parvum and Mycoplasma hominis are microorganisms that reside, as commensals, in the lower urogenital tract but can be responsible for urogenital infections. Three antibiotic families, tetracyclines, fluoroquinolones, and macrolides and related antibiotics, have potent activity against these bacteria but acquired high-level resistance to tetracyclines is associated with the presence of the tet(M) gene, whereas acquired resistance to fluoroquinolones is associated with mutations in the QRDR of the gyrA, gyrB, parC and parE genes. 1 An increasing prevalence of tetracycline and fluoroquinolone resistance has recently been suggested in Ureaplasma spp. in Europe 2 whereas the prevalence of resistance in M. hominis has sparsely been reported worldwide. In France, information on resistance rates is limited. In a previous study, we reported that the percentage of tetracycline-resistant M. hominis isolates increased significantly from 2.8% in 1992 to 18.75% between 1999 and 2002. 3 In contrast, there was no increase in the tetracycline resistance rate of Ureaplasma spp., with a stable rate of 2%-3% between 1992 and 2002. 3 The prevalence of fluoroquinolone resistance has not been studied in M. hominis in France, and only one study reported a prevalence of 0.9% for ofloxacin-resistant Ureaplasma spp. strains between 1989 and 1999. 4 To fill this gap, the aim of this study was to assess the susceptibility of Ureaplasma spp. and M. hominis to tetracyclines and fluoroquinolones in France using commercial kits and the broth V C The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com. microdilution assay. The mechanisms of resistance of resistant isolates were also investigated.
Materials and methods

Clinical samples
Between 1 January 2010 and 31 December 2015, all patient specimens received at the Bordeaux University Hospital (Bordeaux, France) for Ureaplasma spp. or M. hominis detection were cultured at 37 C in Shepard broth medium and Hayflick broth medium supplemented with arginine, respectively. 5 
Antibiotic susceptibility testing
Susceptibility to antibiotics of Ureaplasma spp. and M. hominis isolates was initially evaluated using a calibrated 10 4 -10 5 colour changing units/mL inoculum of each clinical isolate and commercial kits, the S.I.R. Mycoplasma (Bio-Rad, Hercules, CA, USA) from 1 January 2010 to 5 October 2012 and the MYCOFAST RevolutioN kit (ELITechGroup, Puteaux, France), which includes the CLSI breakpoints defined for mycoplasmas, 5 from 6 October 2012 to 31 December 2015. Antibiotic susceptibility testing results were interpreted according to the manufacturer's instructions. For the S.I.R. Mycoplasma kit, which does not include the CLSI breakpoints, resistance was determined by growth in the well containing the highest concentration of antibiotic, i.e. 8 mg/L for tetracycline and 4 mg/L for ofloxacin. When resistance to fluoroquinolones and/or tetracyclines was detected, MICs were systematically determined for tetracycline, ofloxacin, levofloxacin and moxifloxacin by broth microdilution performed in 96-well microtitre plates according to the CLSI guidelines. 5 Accordingly, a total of 157 isolates (141 Ureaplasma spp. and 16 M. hominis) with tetracycline-susceptible results using commercial kits and 50 isolates (41 Ureaplasma spp. and 9 M. hominis) with fluoroquinolone-susceptible results were also evaluated by MIC determination. A range of antimicrobial concentrations from 0.015 to 32 mg/L was used. Antibiotics were purchased from Sigma-Aldrich (St Louis, MO, USA).
Identification of U. parvum and U. urealyticum
Identification of U. parvum and U. urealyticum species was performed by real-time PCR, as previously described, using primers UU-1623F and UU-1524R and two species-specific TaqMan probes, UU-parvo and UU-T960. 6 Characterization of tetracycline-and fluoroquinoloneresistant isolates Bacterial DNA extraction from broth culture of resistant isolates was performed using the NucleoSpin V R Tissue kit (Macherey-Nagel, Hoerdt, France). Amplification and sequencing of the QRDR of gyrA, gyrB, parC and parE genes were performed as previously described 7-9 using primers MHA1, MH4, MH6, MH7, MHC1, MHC2, MH27, MH28, MHE1 and MHE2, respectively, for M. hominis, and primers gyrA-1, gyrA-2, gyrB-3, gyrB-4, parC-5, parC-6, parE-7 and parE-8 for U. parvum. Regarding U. urealyticum, primers gyrA-1, gyrA-2, parC-5, parC-6, parE-7 and parE-8 were also used to amplify gyrA, parC and parE QRDR, but a 52 C hybridization step was used for the amplification of parC and parE QRDR. Primers gyrB-F-UuUp (5 0 -TAGTGAAG TTCGTCCTTATG-3 0 ) and gyrB-R-UuUp (5 0 -GGATCCATTGTTGTTTCTCA-3 0 ) were designed to amplify U. urealyticum gyrB QRDR using a 52 C hybridization step. QRDR amplicons were sent to Eurofins genomics V R for DNA sequencing using the same primers. The sequences were analysed using the BioEdit, 7. The presence of the tet(M) gene was determined by PCR using primers tet1 and tet2, as previously described.
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Statistical analysis
The v 2 test and Fisher's exact test were used to compare the occurrence of resistant isolates that were identified using commercial kits with the occurrence of resistant isolates identified using MICs and to compare the prevalence of resistance over time. P , 0.05 was considered significant.
Results
Evaluation of resistance in Ureaplasma spp. and M. hominis using commercial kits
Of the 831 Ureaplasma spp. isolates tested, 6.3% tetracyclineresistant and 4.2% ofloxacin-resistant isolates were found among the 287 isolates tested by the S.I.R. Mycoplasma kit, and 10.8% tetracycline-resistant, 9.9% levofloxacin-resistant and 3.3% moxifloxacin-resistant isolates were found among the 544 isolates tested by the MYCOFAST RevolutioN kit (Figure 1a ). Of the 183 M. hominis isolates tested, 20.7% tetracycline-resistant and 2.2% ofloxacin-resistant isolates were found among the 92 isolates tested by the S.I.R. Mycoplasma kit, and 9.9% tetracyclineresistant, 3.3% levofloxacin-resistant and 2.2% moxifloxacinresistant isolates were found among the 91 isolates tested by the MYCOFAST RevolutioN kit (Figure 1b ).
MIC determinations
MICs were determined by broth microdilution for all isolates that were found to be resistant to tetracycline and/or fluoroquinolones using commercial kits. For isolates initially found to be resistant using the S.I.R. Mycoplasma kit between 1 January 2010 and 5 October 2012, 5.9% Ureaplasma spp. and 20.7% M. hominis isolates were resistant to tetracycline and 1.4% Ureaplasma spp. and 2.2% M. hominis isolates were resistant to levofloxacin (Table 1) . For isolates initially found to be resistant using the MYCOFAST RevolutioN kit between 6 October 2012 and 31 December 2015, tetracycline resistance was found in 8.3% of Ureaplasma spp. and in 8.8% of M. hominis isolates and levofloxacin resistance in 1.1% Ureaplasma spp. and 3.3% M. hominis isolates (Table 2) . Additionally, the 207 tetracycline-and/or fluoroquinolonesusceptible results from the commercial kits that were checked by MIC determination were all confirmed to be susceptible, except one U. urealyticum isolate for which the tetracycline MIC was 2 mg/L, i.e. only one dilution above the CLSI breakpoint.
Inconsistent results were recorded between the broth microdilution assay used as reference and the MYCOFAST RevolutioN kit for levofloxacin and moxifloxacin resistance detection in Ureaplasma spp. (P , 0.01) (Figure 1 ). The MYCOFAST RevolutioN kit overestimated fluoroquinolone resistance in Ureaplasma spp., as 8.8% (48 of 544) and 3.1% (17 of 544) false cases of levofloxacin and moxifloxacin resistance were identified, respectively. Tetracycline resistance also seemed overestimated in Ureaplasma spp. as 14 (2.6%) false cases of resistance were obtained but the Tetracycline and fluoroquinolone resistance in Ureaplasma spp. and Mycoplasma hominis JAC difference was not statistically significant. No significant difference was found for tetracycline-and fluoroquinolone-resistance detection in M. hominis (Figure 1 ).
Molecular characterization of resistant isolates
The 105 isolates (77 Ureaplasma spp. and 28 M. hominis) detected as tetracycline resistant using commercial kits were screened by PCR for the presence of the tet(M) gene. The tet(M) gene was detected in the 62 Ureaplasma spp. and the 27 M. hominis isolates that were categorized as resistant to tetracycline using MIC determination. The tet(M) gene was not detected in isolates categorized as tetracycline susceptible using MIC determination.
Using MIC determination, a total of nine U. parvum, one U. urealyticum and five M. hominis isolates were categorized as resistant to fluoroquinolones (Table 3 ). Sequence comparison between the QRDR sequences of levofloxacin-resistant isolates and the QRDR sequences of reference strains revealed the presence of the same mutation, Ser83(80)Leu (Ureaplasma spp. numbering with Escherichia coli numbering in parentheses), in ParC in all the Ureaplasma spp. isolates except one. The Val417(410)Thr mutation in ParE was also found in four U. parvum isolates. The only moxifloxacin-resistant U. parvum isolate harboured an additional Figure 1 . Susceptibility distribution of 831 Ureaplasma spp. (a) and 183 M. hominis (b) isolates analysed using S.I.R. Mycoplasma and MYCOFAST RevolutioN kits and using liquid broth MIC determination and CLSI breakpoints. When available, the P value of the comparison between the resistance rate obtained using commercial kits and the resistance rate obtained using MIC determination is shown. TET, tetracycline; R, resistance; OFX, ofloxacin; LVX, levofloxacin; MXF, moxifloxacin; NA, not applicable (no CLSI breakpoints). Because no CLSI breakpoints were defined for ofloxacin, MICs of levofloxacin and moxifloxacin were determined for the 12 Ureaplasma spp. and the 2 M. hominis isolates that were categorized as resistant to ofloxacin using the commercial kit. Tetracycline and fluoroquinolone resistance in Ureaplasma spp. and Mycoplasma hominis JAC Table 3 . Meygret et al.
Gln104(87)Lys mutation in the gyrA gene. In all of the five levofloxacin-resistant M. hominis isolates, ParC and/or ParE mutations were found, the most frequent being Ser91(80)Ile (M. hominis numbering with E. coli numbering in parenthesis) ( Table 3) . The three M. hominis isolates that were also resistant to moxifloxacin harboured the same additional Ser153(83)Leu mutation in GyrA. No mutation was detected in the gyrB gene for any M. hominis isolates.
Changes in resistance prevalence over 6 years
Between 2010 and 2015, no statistically significant changes were found in the prevalence of tetracycline and fluoroquinolone resistance in Ureaplasma spp. and M. hominis (Table 4 ). The overall tetracycline resistance prevalence of 7.5%-14.8% according to the species was higher than the fluoroquinolone resistance prevalence, which remained ,1.2% for Ureaplasma spp. and ,2.7% for M. hominis.
Discussion
Susceptibility testing methodology
The limited therapeutic options available to combat infections caused by urogenital mycoplasmas justify the importance of studying the prevalence and mechanisms of resistance. However, according to the methodology of detection, resistance data may not be comparable. 2 In the present study, as recommended in the recent literature, 2 antimicrobial susceptibility testing using commercial kits was performed using purified cultures of Ureaplasma spp. and M. hominis isolates. In addition, dilutions were previously performed to calibrate accurately the inoculum that was added to the test panel. In this study, we demonstrated that the MYCOFAST RevolutioN kit overestimated fluoroquinolone resistance in Ureaplasma spp. isolates, suggesting that, when this kit is used in routine diagnosis, fluoroquinolone resistance should be confirmed in Ureaplasma spp. with broth microdilution assay according to CLSI guidelines.
A limitation of this study is that two different commercial kits were used to detect resistant isolates and that their performance may be different. Notably, the S.I.R. Mycoplasma kit does not include the CLSI breakpoints defined for tetracycline against mycoplasmas and includes ofloxacin as the only fluoroquinolone, for which no specific breakpoints were defined for mycoplasmas. Criteria for the definition of resistance in the S.I.R. Mycoplasma kit were chosen by the manufacturer by using the breakpoints defined by the French Society for Microbiology for classic bacteria at the time the kit was developed. In the present study, tetracycline, levofloxacin and moxifloxacin MICs for all isolates detected as resistant using both commercial kits were subsequently determined and interpreted according to the CLSI guidelines and breakpoints specifically defined for mycoplasmas, 5 which ensure data homogeneity. Moreover, because ofloxacin is less potent than levofloxacin and moxifloxacin against Ureaplasma spp. and M. hominis, 12, 13 we believe that no levofloxacin or moxifloxacinresistant isolates could have been missed using the S.I.R. Mycoplasma kit between 2010 and 2012. Additionally, .200 tetracycline-or fluoroquinolone-susceptible results obtained with both commercial kits were confirmed to be susceptible by MIC determination, suggesting that resistance was not under-reported in this study.
Resistance prevalence comparison
In Ureaplasma spp., we previously reported a rate of tetracycline resistance in France of 2.2% (6 of 276) between 1999 and 2002. 3 This rate significantly increased in 2010-15 in France, with an overall resistance rate of 7.5% (62 of 831) (P , 0.01). The increase in Ureaplasma spp. tetracycline resistance in a decade is of concern because tetracycline is the first-line treatment for adult urogenital infections. Resistance rates were recently determined for Ureaplasma spp. in other countries using the MYCOFAST RevolutioN or microdilution assay. Indeed, the 7.5% French rate was higher than in Switzerland in 2014 (0% of 103 isolates), 14 in the USA in 2015-16 (0.4% of 250 isolates) 15 and in England between 2007 and 2013 (2.3% of 130 isolates).
16 Surprisingly, a In the present study, levels of levofloxacin and moxifloxacin resistance in Ureaplasma spp. were low at 1.2% and 0.1%, respectively. This rate is similar to that described for ofloxacin in France in the 1990s (0.9%). 4 Considering only recent studies, which used the microdilution broth assay, this low rate of resistance is in accordance with the 6% (15 of 250) of levofloxacin-resistant Ureaplasma spp. isolates reported between 2015 and 2016 in the USA 15 and the absence of levofloxacin-resistant isolates reported between 2007 and 2013 in England. 16 In contrast, 57% (16 of 28) of levofloxacinresistant Ureaplasma spp. isolates were reported in Japan. 18 Regarding M. hominis, our study did not show any significant change in the tetracycline resistance rate, which was 18.75% (24 of 128) during 1999-2002 3 and 14.8% (27 of 183) during 2010-15 (P . 0.05).
Molecular characterization of fluoroquinolone-resistant isolates
All levofloxacin-resistant Ureaplasma spp. isolates except one harboured the Ser83(80)Leu substitution in the parC gene, which was alone responsible for resistance in 60% of cases. This mutation has previously been reported as being the most frequent mutation responsible for fluoroquinolone resistance in Ureaplasma spp. worldwide. 4, 15, [18] [19] [20] The previously reported Val417(410)Thr substitution in ParE [19] [20] [21] was the second most frequent mutation. Resistance to moxifloxacin was associated with the additional Gln104(87)Lys mutation in the gyrA gene. This mutation was previously associated with an increased fluoroquinolone resistance level and is located within one of the GyrA hot spots for fluoroquinolone resistance. 19, 20, 22 In M. hominis, all levofloxacin-resistant isolates harboured a substitution previously associated with fluoroquinolone resistance in ParC or ParE. 4, 9, 23, 24 Resistance to moxifloxacin was associated with the additional Ser153(83)Leu mutation in GyrA; this mutation was previously associated with a high level of resistance to fluoroquinolones. 7 Overall, all levofloxacin-resistant isolates characterized in this study harboured a previously reported mutation in the parC and parE genes, and in the gyrA gene in the case of moxifloxacin resistance.
In conclusion, this work extends previous knowledge regarding susceptibility to antimicrobial agents and resistance mechanisms in Ureaplasma spp. and M. hominis in France. Notably, compared with the previous report in 1999-2002 in France, a significant increase in tetracycline resistance up to 7.5% was observed in Ureaplasma spp. and a 14.8% tetracycline resistance rate was described in M. hominis. These findings confirm the necessity to monitor the antibiotic susceptibility of human urogenital mycoplasmas.
